Literature DB >> 17353640

[A resected case of squamous cell carcinoma of the breast successfully treated by FU plus cisplatin (CDDP) adjuvant therapy against recurrent metastases].

Kiyoshi Hiramatsu1, Kenji Kato, Akihiro Hirata, Hideki Matsuba, Tomohiro Hara, Takaaki Ito, Taishi Miyata, Takashi Akagawa, Yasushi Kutsuna, Yuichi Machiki, Susumu Fujioka.   

Abstract

A resected case of squamous cell carcinoma associated with ductal carcinoma in the hemilateral breast successfully treated by FU plus cisplatin (CDDP) adjuvant therapy against recurrent metastases is reported with some discussion. A 42-year-old woman was admitted to our hospital because of right breast tumor. By physical examination, mammography, ultrasound examination and aspirated cytology, we diagnosed squamous cell carcinoma of the right breast. Before operation SCC antigen was elevated. Standard mastectomy was performed, and SCC antigen was decreased within normal range. Then, a standard regimen of chemotherapy using docetaxel with anti-hormonal therapy by LH-RH analog and tamoxifen was done as first-line adjuvant therapy. Four months after operation the SCC antigen level was elevated again, and recurrence of cancer (skin and liver metastases) was recognized. Next, we tried 5-FU/UFT plus CDDP for squamous cell carcinoma of other organs such as the esophagus. These anti-tumor drugs proved effective, and no metastasis of the skin was detected thereafter, and liver metastatic lesion was decreased in ten months. The SCC antigen level was within the normal range again. Additionally, when metastases redeveloped, TS-1 plus CDDP controlled growth of tumors in seven months. Based on the present findings,we recommend adjuvant chemotherapy by FU plus CDDP for squamous cell carcinoma of the breast.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17353640

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  9 in total

1.  Primary squamous cell carcinoma of the breast.

Authors:  Sachin A Badge; Nitin M Gangane; Vitaladevnni B Shivkumar; Satish M Sharma
Journal:  Int J Appl Basic Med Res       Date:  2014-01

Review 2.  Management of unusual histological types of breast cancer.

Authors:  Karen A Cadoo; Orla McArdle; Anne-Marie O'Shea; Colm P Power; Bryan T Hennessy
Journal:  Oncologist       Date:  2012-07-23

3.  Clinicopathological analysis of ten patients with metaplastic squamous cell carcinoma of the breast.

Authors:  Michitaka Honda; Shigehira Saji; Shin-ichiro Horiguchi; Eiji Suzuki; Tomoyuki Aruga; Kazumi Horiguchi; Dai Kitagawa; Susumu Sekine; Nobuaki Funata; Masakazu Toi; Katsumasa Kuroi
Journal:  Surg Today       Date:  2011-03-02       Impact factor: 2.549

4.  Primary squamous cell carcinoma of the breast: A rare case report.

Authors:  Stefania Carbone; Rosabel Lobo Alvarez; Annalisa Lamacchia; Asuncion Almenar Gil; Raquel Martin Hernandez; Jose Luis Lopez Guerra; Hugo Marsiglia
Journal:  Rep Pract Oncol Radiother       Date:  2012-08-09

5.  Primary squamous cell carcinoma of the breast in a young female- A rare ailment.

Authors:  Suraj Shrestha; Prafulla Shakya; Sanjeev Kharel; Hari Prasad Dhakal; Moushami Singh; Aagon Krishna Shrestha
Journal:  Clin Case Rep       Date:  2021-05-24

6.  Squamous cell carcinoma of the breast: a case report.

Authors:  Roberto Murialdo; Davide Boy; Yuri Musizzano; Lucia Tixi; Federica Murelli; Alberto Ballestrero
Journal:  Cases J       Date:  2009-07-10

7.  Primary pure squamous cell carcinoma of the breast might be sensitive to Cisplatin-based chemotherapy.

Authors:  Swei H Tsung
Journal:  Case Rep Oncol       Date:  2012-10-16

Review 8.  Primary squamous cell carcinoma of the breast: a case report and review of literature.

Authors:  Youssef Seddik; Sami Aziz Brahmi; Said Afqir
Journal:  Pan Afr Med J       Date:  2015-02-18

9.  Prognostic factors for breast cancer squamous cell carcinoma and nomogram development for prediction: population-based research.

Authors:  Zhiyuan Cheng; Tao Han; Xiaotian Zhang; Xizhou Li; Hengyu Li; Jia Gu
Journal:  Transl Cancer Res       Date:  2019-09       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.